---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032289"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:32:33.405442+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# BioCardia enrolls first patient at Wisconsin in Phase 3 CardiAMP HF II trial

## Summary
- First patient enrolled at University of Wisconsin School of Medicine and Public Health in Phase 3 CardiAMP HF II trial.
- Trial is 250-patient randomized placebo-controlled study for ischemic HFrEF patients with elevated NTproBNP.
- Dr. Amish Raval serves as national co-principal investigator; UW is a prestigious cardiology center.
- Therapy uses autologous cells; cell population analysis defines doses; Helix system includes Morph DNA steerable platform.

## SEC filing metadata
- accession: 0001437749-25-032289
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925032289/0001437749-25-032289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925032289/bcda20251030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032289
- JSON: https://secwatch.observer/filing/0001437749-25-032289.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.